CEO Kabir Nath highlighted "the potential 9- to 12-month acceleration of our launch plans that we announced today" as a key update, citing the completion of enrollment for the COMP006 Phase III trial ...

COMPASS Pathways has delivered a powerful 3 year share price gain, even after a recent pullback, and fresh clinical progress ...

Compass Pathways has partnered with mental health organizations on the first-ever awareness day for treatment-resistant ...

COMPASS Pathways (CMPS) is back in focus after recent share price swings, with the mental health biotech drawing attention as investors reassess its psilocybin-based COMP360 pipeline and current ...

Some of the most important upcoming catalysts for Compass' stock have little to do with its own research and development (R&D) or business development activities. Lykos Therapeutics, a psychedelic ...

The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared ...

Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants Training guidance is designed to prepare healthcare ...

The precipitous fall occurred on Monday, 06/23/2025 when the stock dropped from its close at $4.63 on the previous Friday to open Monday at $3.08. It hit an interday low of $2.25, closing the hectic ...

Compass is a newly founded British company that is moving to commercialize the long-studied therapeutic impact of psilocybin. Both market acceptance issues and bad trip potential are risks of its ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June LONDON & NEW YORK--(BUSINESS WIRE)--Compass ...

COMPASS Pathways stock (ISIN US20451W1018) stood at USD 13.75 in after-hours trading on Nasdaq on September 23, 2026, down 6.97 percent from the previous close of USD 14.78. The move followed a TD ...